Home › Carcinoma a cellule squamose della testa e del collo › South Carolina › Charleston
Studi clinici su Carcinoma a cellule squamose della testa e del collo a Charleston, SC
14 studi su Carcinoma a cellule squamose della testa e del collo cercano partecipanti presso sedi a Charleston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
In reclutamentoFase 2/3
- Site#0104, Charleston
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
In reclutamentoFase 3
- Medical University of South Carolina, Charleston
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
In reclutamentoFase 2
- Medical University of South Carolina, Charleston
Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
In reclutamentoFase 2
- Medical University of South Carolina, Charleston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
In reclutamentoFase 1
- Normunity Investigational Site, Charleston
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
In reclutamentoFase 2/3
- Medical University of South Carolina, Charleston
Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
In reclutamentoFase 2
- Medical University of South Carolina Hollings Cancer Center, Charleston
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
In reclutamentoFase 3
- GSK Investigational Site, Charleston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 2
- USA03-0, Charleston
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
In reclutamentoFase 2
- Medical University of South Carolina, Charleston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
In reclutamentoFase 3
- Medical University of South Carolina (MUSC), Charleston
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
In reclutamento
- Medical University of South Carolina, Charleston
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 1/2
- Research Site 123, Charleston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
In reclutamentoFase 1
- Medical University of South Carolina, Hollings Cancer Center, Charleston
Studi su Carcinoma a cellule squamose della testa e del collo in altre città
- Houston, TX47 studi
- Los Angeles, CA42 studi
- Boston, MA40 studi
- Nashville, TN39 studi
- New York City, NY39 studi
- St. Louis, MO28 studi
- Arlington, VA26 studi
- Chicago, IL26 studi
- Philadelphia, PA26 studi
- Atlanta, GA24 studi
- San Antonio, TX22 studi
- Pittsburgh, PA22 studi
Altri studi a Charleston
- Depressione19 studi
- Ictus18 studi
- Insufficienza cardiaca18 studi
- Cancro del polmone non a piccole cellule16 studi
- Disturbo da stress post-traumatico16 studi
- Malattie cardiovascolari15 studi
- Cancro alla prostata15 studi
- Cancro (tutti i tipi)14 studi
- Morbo di Parkinson13 studi
- Malattie polmonari interstiziali13 studi
- Cancro al seno12 studi
- Cancro ai polmoni11 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.